Aurobindo Pharma's CuraTeQ ends biosimilar pact with BioFactura

• Aurobindo Pharma's subsidiary, CuraTeQ Biologics, mutually terminated its license agreement with US-based BioFactura Inc.
• The pact was for the commercialization of BFI-751, a proposed biosimilar of ustekinumab (Stelara).
• Decision followed a strategic review and aligns with CuraTeQ’s portfolio prioritization efforts.
• Termination is effective December 27, 2025, and is not expected to materially impact Aurobindo's biosimilars strategy.
• CuraTeQ held global manufacturing rights and profit-sharing under the original July 2023 agreement.

Why It Matters: CuraTeQ ended its biosimilar agreement with BioFactura due to strategic review, but Aurobindo's overall biosimilar strategy remains unaffected.